Related Experiment Video
Updated: Jun 4, 2025
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
Q11, a CYP2E1 inhibitor, exerts anti-hepatocellular carcinoma effect by inhibiting M2 macrophage polarization
Cunzhen Zhang1, Yan Fang1, Mengxue Guo1
1Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, 450001, China.
Abstract:
Despite significant advancements in cancer immunotherapy, many patients continue to respond poorly. Novel therapeutic strategies and drugs are urgently needed. Here, we found that CYP2E1 is upregulated in M2 macrophages. The CYP2E1 inhibitor, Q11, could inhibit M2 macrophage polarization, while CYP2E1 overexpression could promote it. Increased levels of CYP2E1 and M2 macrophages in the tumor microenvironment of HCC patients correlate with poor prognosis. Q11 could inhibit tumor cells by targeting M2 macrophages rather than directly attacking tumor cells. Both Q11 and Cyp2e1 knockout could effectively suppress tumor growth. Q11 reduces the production of CYP2E1 metabolites ( ±)9(10)-DiHOME and ( ±)12(13)-DiHOME, thus attenuating PPARγ activation and M2 macrophage polarization. In summary, our findings suggest that Q11 could suppress M2 macrophage polarization by modulating the CYP2E1/( ±)9(10)-DiHOME or ( ±)12(13)-DiHOME/PPARγ axis, indicating that CYP2E1 may be a potential therapeutic target for HCC, and its inhibitor Q11 may be a potential drug for the treatment of HCC.
Insights
A new study reveals that targeting CYP2E1 in M2 macrophages with the inhibitor Q11 can suppress hepatocellular carcinoma (HCC) growth. This approach offers a promising therapeutic strategy for patients with poor immunotherapy response.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Cancer immunotherapy shows limited efficacy in many patients, necessitating novel therapeutic strategies.
- M2 macrophages play a role in the tumor microenvironment and cancer progression.
Purpose of the Study:
- To investigate the role of Cytochrome P450 2E1 (CYP2E1) in M2 macrophage polarization and its potential as a therapeutic target in hepatocellular carcinoma (HCC).
Main Methods:
- Examined CYP2E1 expression in M2 macrophages and HCC patient tumors.
- Utilized a CYP2E1 inhibitor (Q11) and gene knockout models.
- Assessed the impact on M2 macrophage polarization, metabolite production (DiHOMEs), and tumor growth.
- Investigated the involvement of the PPARγ signaling pathway.
Main Results:
- CYP2E1 is upregulated in M2 macrophages and its levels correlate with poor prognosis in HCC patients.
- Inhibition of CYP2E1 by Q11 suppressed M2 macrophage polarization and tumor growth.
- Q11 reduced CYP2E1 metabolites (DiHOMEs), attenuated PPARγ activation, and inhibited M2 polarization.
- CYP2E1 knockout also suppressed tumor growth, confirming CYP2E1's role.
Conclusions:
- CYP2E1 is a key regulator of M2 macrophage polarization via the DiHOME/PPARγ axis.
- Targeting CYP2E1 with Q11 represents a potential therapeutic strategy for HCC by modulating the tumor microenvironment.
More Related Videos
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
